CRIS
Curis IncstockNASDAQ
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis's pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.57 | 2026-11-12 | +6.61% | -2.785 |
| 1M | 0.38 | 2026-10-19 | +59.75% | 2.762 |
| 3M | 1.72 | 2026-08-19 | -64.56% | 1.874 |
| 6M | 0.48 | 2026-05-19 | +28.12% | 15.700 |
| 1Y | 1.13 | 2025-11-19 | -46.05% | 9.249 |
| 2Y | 3.79 | 2024-11-19 | -83.92% | — |
| 5Y | 102.60 | 2021-11-19 | -99.41% | 2.008 |
Curis Inc (NASDAQ:CRIS) stock price today is $0.61, and today's volume is 10,640,979. CRIS is up 12.514% today. The 30 day average volume is 9.02M. CRIS market cap is $4.07M with 6.68M shares outstanding.
